No CrossRef data available.
Article contents
Selective reporting of fluoroquinolone susceptibility as a stewardship measure is of marginal benefit
Published online by Cambridge University Press: 14 April 2020
Abstract
A retrospective time series analysis was conducted to compare inpatient fluoroquinolone use when susceptibilities were masked and after susceptibilities were unmasked. Although inappropriate culture-directed prescriptions increased, overall fluoroquinolone usage decreased. Culture-directed therapy was a small part of fluoroquinolone usage; hence, efforts should target empiric use to reduce overall consumption.
- Type
- Concise Communication
- Information
- Copyright
- © 2020 by The Society for Healthcare Epidemiology of America. All rights reserved.
References
Paterson, DL.“Collateral damage” from cephalosporin or quinolone antibiotic therapy. Clin Inf Dis 2004;38 supplement 4: S341–S345.CrossRefGoogle Scholar
Al-Tawfiq, JA, Momattin, H, Al-Habboubi, F.Dancer, SJ.Restrictive reporting of selected antimicrobial susceptibilities influences clinical prescribing. J Infect Public Health 2015;8:234–241.CrossRefGoogle ScholarPubMed
Langford, BJ, Seah, J, Chan, A, Downing, M, Johnstone, J, Matukas, LM.Antimicrobial stewardship in the microbiology laboratory: impact of selective susceptibility reporting on ciprofloxacin utilization and susceptibility of gram-negative isolates to ciprofloxacin in a hospital setting. J Clin Microbiol 2016;54:2343–2347.10.1128/JCM.00950-16CrossRefGoogle ScholarPubMed
Pulcini, C, Tebano, G, Mutters, NT, et al.Selective reporting of antibiotic susceptibility test results in European countries: an ESCMID cross-sectional survey. Int J Antimicrob Agents 2017;49:162–166.CrossRefGoogle ScholarPubMed
FDA Drug Safety Communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. US Food & Drug Administration website. https://www.fda.gov/Drugs/DrugSafety/ucm511530.htm Published 2016. Accessed May 23, 2017.Google Scholar
Barlam, TF, Cosgrove, SE, Abbo, LM, et al.Implementing an antibiotic stewardship program: guidelines by the infectious diseases society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis 2016;62(10):e51–e77.10.1093/cid/ciw118CrossRefGoogle Scholar
Surveillance atlas of infectious diseases. European Centre for Disease Prevention and Control website. http://atlas.ecdc.europa.eu/public/index.aspx?Instanceprotect%20$%0Delax%20=$GeneralAtlas. Accessed November 28, 2019.Google Scholar
Sanchez, GV, Master, RN, Clark, RB, et al.Klebsiella pneumoniae antimicrobial drug resistance, United States, 1998–2010. Emerg Infect Dis 2013;19:133–136.10.3201/eid1901.120310CrossRefGoogle ScholarPubMed
Elligsen, M, Walker, SA, Pinto, R, et al.Audit and feedback to reduce broad-spectrum antibiotic use among intensive care unit patients: a controlled interrupted time series analysis. Infect Control Hosp Epidemiol 2012;33:354–361.10.1086/664757CrossRefGoogle ScholarPubMed
Lewis, GJ, Fang, X, Gooch, M, et al.Decreased resistance of Pseudomonas aeruginosa with restriction of ciprofloxacin in a large teaching hospital’s intensive care and intermediate care units. Infect Control Hosp Epidemiol 2012;33:368–373.CrossRefGoogle Scholar
Ting Ting et al. supplementary material
Table S1
File
13.9 KB